|
Oct 2
|
Navigating Legal Uncertainty: Nuvation Bio Inc.’s Chinese Operations and the Shifting Landscape of China’s Civil Law System
|
|
Jul 23
|
Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib
|
|
May 14
|
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
Apr 24
|
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
Apr 10
|
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
|
|
Mar 28
|
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
|
|
Mar 25
|
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
|
|
Mar 14
|
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
|
|
Mar 8
|
Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know
|
|
Jan 8
|
Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors
|
|
Jan 8
|
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors
|
|
Dec 4
|
Companies Like Nuvation Bio (NYSE:NUVB) Are In A Position To Invest In Growth
|
|
Aug 3
|
Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
|